Dyne Therapeutics, Inc. 4

Chief Medical Officer Douglas Kerr sold 1,556 shares of Dyne Therapeutics, Inc. common stock at about $26.28 per share to cover taxes upon RSU vesting.

On August 13, 2026, Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr had 1,556 shares of common stock automatically sold at a weighted average price of approximately $26.28 per share, generating proceeds of about $40,900, solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units under a pre-arranged Rule 10b5-1-compliant contract, leaving him with direct ownership of 167,599 shares, including 140,001 unvested RSUs.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

fda

Accession

0001814189-26-000004

Alert Tier

5